Navigation Links
NovoBioPharma, Partnership of Top Life Science Experts, Launches
Date:6/11/2013

CAMBRIDGE, Mass., June 11, 2013 /PRNewswire/ -- NovoBioPharma, a partnership of experts collaborating with life science organizations to provide comprehensive medical, scientific, regulatory, business and financial advisory services, launched today. The global business is comprised of four principals, all experts in their fields, who partnered to create an entity to help life science companies and institutions to cost-efficiently advance drug, diagnostic and device candidates by leveraging opportunities from conception through clinical development, and ultimately, regulatory approval.

With decades of experience and a global network in all areas of business, finance, drug, diagnostic and device development, NovoBioPharma offers services in capital sourcing and management, business development, intellectual property, quality control, manufacturing, study design, and protocol development. Simply put, NovoBioPharma covers every facet of the risky and costly work of developing life science breakthroughs.

The NovoBioPharma team is:

Bernie Rudnick, MBA, Chief Business Officer, is founder and managing partner of CapGenic Advisors, LLC, and a founding member of several Angel investing groups. Mr. Rudnick has substantial experience investing and guiding investments in entrepreneurial companies; he has led capital formation totaling more than $530 million in the past ten years and $3B during the last 15 years. Mr. Rudnick, a serial entrepreneur, founded, managed and advised numerous companies in the life sciences, including diagnostic, therapeutic and clinical software environments.  Mr. Rudnick is experienced in forms of capital formation including angel networks, venture capital funds, SBIR and other government grant programs. He is a graduate of Penn State and Northwood University.

Ira Wallace, MD, MBA is Chief Development Officer for NovoBioPharma. Dr. Wallace has been involved in pharmaceutical, biotech and medical device companies as a CEO, founder, board member and consultant.  In addition, Dr. Wallace is experienced in technology transfer and intellectual property strategies and is a founding member and partner in a number of Angel investment groups. A graduate of the University of Pennsylvania, Dr. Wallace earned his medical degree at Drexel Medical School and his MBA at Columbia.

Shahin Gharakhanian MD, Head, Pharmaceutical Medicine, is an infectious diseases and internal medicine trained physician with over 20 years experience in the pharmaceutical industry and clinical practice. His last position was Vice President in the Medicines Development Group/Global R&D at Vertex Pharmaceuticals, Inc. Cambridge MA, USA. In industry, Dr. Gharakhanian has driven: strategic leadership, clinical development and medical affairs. Overall, he has handled projects for twelve different pharmaceutical companies, ten different brands and four drug launches in Asia, Canada, EU and the United States. His most recent major New Drug Application/launch experience was in 2011. Dr. Gharakhanian earned his specialty medical degrees at University of Paris, and trained/practiced in AP-HP, Paris, France, the largest hospital system in Europe and one of the largest in the world.

Andrew D. Luber, PharmD Chief Scientific Officer, is an infectious diseases trained clinical pharmacist/pharmacologist with over 18 years experience working with the pharmaceutical industry as an investigator, key opinion leader, speakers bureau, steering committee and advisory board member.  In addition, he has served as a clinical consultant to large and early stage pharmaceutical companies.  Dr. Luber has been an investigator in more than 70 clinical trials including four Phase 1a first in human studies and specializes in early stage drug development. Dr. Luber received his doctor of pharmacy at Temple University and did his post-doctoral residencies and research fellowship at the University of California, San Francisco Medical Center and School of Pharmacy.

For more information, visit the website at NovoBioPharma
Contact:  Andrew D. Luber, PharmD 1-856-258-0850


'/>"/>
SOURCE NovoBioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis and Medicines360 Announce Partnership to Advance Womens Access to Affordable IUDs
2. Elekta-Equra Health Partnership to Increase South African Cancer Patients Access to Radiation Therapy
3. AmeriCares Honors Merck with Power of Partnership Award
4. PDR Network and OPTIMIZERx (SampleMD) Announce Partnership to Deliver Patient Financial Support Programs Within EHR Workflow
5. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
6. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
7. Life Line Screening and MCM Solutions for Better Health Announce New Partnership
8. United Way and FamilyWize Partnership Has Helped 5 Million People Stay Healthy
9. Allergans Global Dominance in Facial Injectables Challenged by Acquisitions and Partnership Agreements Among Competitors
10. Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments
11. Huahai and Oncobiologics Create Broad Biosimilars Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
(Date:3/24/2017)... March 24, 2017 Global Ampoules ... including definitions, classifications, applications and industry chain structure. The ... including development history, competitive landscape analysis, and major regions, ... ... across 105 pages providing 10 company profiles and 183 ...
(Date:3/24/2017)... 24, 2017  GenomeDx Biosciences today announced that six ... Decipher® Prostate Cancer Classifier tests will be presented at ... (EAU) Congress held March 24 to 28, 2017 in ... Congress is Europe,s largest urological ... the urological field. The abstract titled "Muscle ...
Breaking Medicine Technology:
(Date:3/23/2017)... Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... emergency and now estimates that there could be four million Zika-related cases in the ... to date with numbers of US cases reported per year skyrocketing to an estimated ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the ... huge impact on businesses and individual consumers alike. Laboratories can maximize their profit ... value anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey ...
(Date:3/23/2017)... ... March 23, 2017 , ... Dilger-Maxwell ... of the Norwalk and Vermillion areas, celebrates the newest charity campaign in ... nonprofit, community-based substance abuse prevention and peer recovery support organization providing vital ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Management Accreditation from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, ... status is granted to organizations that have excellent programs for the delivery and ...
Breaking Medicine News(10 mins):